Metolazone
Sulfonamides, Plain
Sold as ZAROXOLYN
- Drug class
- Sulfonamides, Plain
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 6
- FDA reports (12 mo)
- 511
Overview
Plain-language summary, compiled from the cited regulatory records
Metolazone is a medication belonging to the sulfonamide class of drugs [1]. It is approved for treating fluid and salt retention associated with conditions such as congestive heart failure and various renal diseases, including nephrotic syndrome and impaired kidney function [1]. Additionally, metolazone is indicated for managing hypertension, either as a standalone treatment or in combination with other types of antihypertensive medications [1].
In the market, metolazone is available under several brand names [N]. Over the past 12 months, there have been 511 adverse event reports associated with metolazone [2]. The most frequently reported adverse events include dyspnoea, headache, diarrhoea, off-label use, and nausea [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 4 | March 19, 2025 |
| GB United Kingdom | MHRA | 1 | February 20, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
USUnited States· FDA
4 products
Uses
INDICATIONS AND USAGE
Metolazone is indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function.
Metolazone is also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension.
A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. Usage In Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard.
GBUnited Kingdom· MHRA
1 product
Uses
Xaqua is indicated for the treatment of • oedema related to kidney diseases, including the nephrotic syndrome and states of impaired renal function • oedema related to congestive heart failure Xaqua is also indicated for the treatment of mild and moderate hypertension, alone or in combination with other antihypertensive medicines of a different class.
How to take
CACanada· Health Canada
1 product
Uses
ZAROXOLYN (metolazone tablets) is indicated for: the treatment of edema accompanying congestive heart failure and edema accompanying renal diseases including the nephrotic syndrome, and states of diminished renal function. the management of mild to moderate essential hypertension, alone or in combination with other antihypertensive drugs of a different class.
3 Pediatrics). 2 Geriatrics Geriatrics: Due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy, elderly patients should be treated with caution, usually starting at the low end of the dosing range.
How to take
Drug interactions
Known interactions involving Metolazone. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 517. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 08cb093a-b8ec-40… · revised December 24, 2024 [PDF]
- [2]MHRA (UK) · PL446960010 · revised February 20, 2026
- [3]Health Canada (DPD) · 00888400 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.